1. Medtech Insight
  2. >>Policy & Regulation

Labs Have Two More Months To Report Private-Payer Data, CMS Says

 
• By Sue Darcey

The US Medicare agency will allow laboratories two additional months – until May 30, 2017 – to report their private-payer pricing data, which will serve as the basis for clinical laboratory Medicare reimbursements starting in January. The agency said it is responding to industry feedback that more time is needed to collect the data.

The Center for Medicare and Medicaid Services will exercise "enforcement discretion" for two more months, giving laboratories until May 30, 2017 to report their private-payer pricing data to the agency, as required under the Protecting Access to Medicare Act, the agency announced March 30.

PAMA requires labs to report payment rates from private insurers and test volumes to support a transition to market-based Medicare reimbursement for lab tests. (Also see "Labs Get Extra...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.